{"id":"https://openalex.org/W1999892123","doi":"https://doi.org/10.1111/dom.12149","title":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double\u2010blind, placebo\u2010controlled, 12\u2010week study","display_name":"Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double\u2010blind, placebo\u2010controlled, 12\u2010week study","alternate_titles":[],"publication_year":2013,"publication_date":"2013-07-14","ids":{"openalex":"https://openalex.org/W1999892123","doi":"https://doi.org/10.1111/dom.12149","mag":"1999892123","pmid":"https://pubmed.ncbi.nlm.nih.gov/23782594","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/3906835"},"language":"en","primary_location":{"id":"doi:10.1111/dom.12149","doi":"https://doi.org/10.1111/dom.12149","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12149","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12149","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1999892123"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12149","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077189198","display_name":"Nobuya Inagaki","orcid":"https://orcid.org/0000-0001-8261-2593","observed_orcids":["https://orcid.org/0000-0001-8261-2593"]},"institutions":[{"id":"https://openalex.org/I22299242","display_name":"Kyoto University","ror":"https://ror.org/02kpeqv85","country_code":"JP","type":"education","lineage":["https://openalex.org/I22299242"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Inagaki","raw_affiliation_strings":["Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto Japan","institution_ids":["https://openalex.org/I22299242"]}]},{"author_position":"middle","author":{"id":null,"display_name":"K. Kondo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. Kondo","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075196043","display_name":"Toru Yoshinari","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"T. Yoshinari","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050540836","display_name":"Nobuko Maruyama","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"N. Maruyama","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060684644","display_name":"Yutaka Susuta","orcid":"https://orcid.org/0000-0003-1621-9261","observed_orcids":["https://orcid.org/0000-0003-1621-9261"]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Y. Susuta","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033051249","display_name":"Hideki Kuki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4387155982","display_name":"Tanabe Pharma Corporation (Japan)","ror":"https://ror.org/038ehsm73","country_code":"JP","type":"company","lineage":["https://openalex.org/I168192097","https://openalex.org/I4387155982"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"H. Kuki","raw_affiliation_strings":["Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan","institution_ids":["https://openalex.org/I4387155982"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5075196043"],"corresponding_institution_ids":["https://openalex.org/I4387155982"],"apc_list":{"value":5380,"currency":"USD","value_usd":5380},"apc_paid":{"value":5380,"currency":"USD","value_usd":5380},"fwci":12.0966,"has_fulltext":true,"cited_by_count":145,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.9914468,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":100},"biblio":{"volume":"15","issue":"12","first_page":"1136","last_page":"1145"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/canagliflozin","display_name":"canagliflozin","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.8610000014305115},{"id":"https://openalex.org/keywords/sglt2-inhibitors","display_name":"SGLT2 inhibitors","score":0.9559999704360962},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9010000228881836},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9869999885559082},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.8920000195503235},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.9020000100135803},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.8389999866485596},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8399999737739563},{"id":"https://openalex.org/keywords/urinary-albumin-creatinine-ratio","display_name":"urinary albumin-creatinine ratio","score":0.8330000042915344},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.6159999966621399},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.9549999833106995},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5709999799728394},{"id":"https://openalex.org/keywords/diet-and-exercise-therapy","display_name":"diet and exercise therapy","score":0.8899999856948853},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.652999997138977},{"id":"https://openalex.org/keywords/serum-creatinine","display_name":"serum creatinine","score":0.7990000247955322},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.44200000166893005}],"concepts":[{"id":"https://openalex.org/C2777451236","wikidata":"https://www.wikidata.org/wiki/Q5030940","display_name":"Canagliflozin","level":4,"score":0.9822771549224854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8202319145202637},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7393948435783386},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.6741535663604736},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5704418420791626},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5696668028831482},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5507064461708069},{"id":"https://openalex.org/C2780306776","wikidata":"https://www.wikidata.org/wiki/Q426660","display_name":"Creatinine","level":2,"score":0.48303160071372986},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47918856143951416},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4725235104560852},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.41165101528167725},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.40114885568618774},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3584548234939575},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3457774221897125},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000068896","descriptor_name":"Canagliflozin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D005960","descriptor_name":"Glucosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013876","descriptor_name":"Thiophenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1111/dom.12149","doi":"https://doi.org/10.1111/dom.12149","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12149","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12149","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:2897271","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/3906835","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:3906835","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3906835/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes Obes Metab","raw_type":"Text"},{"id":"pmid:23782594","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23782594","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, obesity & metabolism","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1111/dom.12149","doi":"https://doi.org/10.1111/dom.12149","is_oa":true,"landing_page_url":"https://doi.org/10.1111/dom.12149","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dom.12149","source":{"id":"https://openalex.org/S148394532","display_name":"Diabetes Obesity and Metabolism","issn_l":"1462-8902","issn":["1462-8902","1463-1326"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Diabetes, Obesity and Metabolism","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320327566","display_name":"Mitsubishi Tanabe Pharma Corporation","ror":"https://ror.org/038ehsm73"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1999892123.pdf","grobid_xml":"https://content.openalex.org/works/W1999892123.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W1997018189","https://openalex.org/W2013962406","https://openalex.org/W2016622896","https://openalex.org/W2050614267","https://openalex.org/W2068171948","https://openalex.org/W2071477116","https://openalex.org/W2081276121","https://openalex.org/W2084511068","https://openalex.org/W2090088543","https://openalex.org/W2107146663","https://openalex.org/W2118613762","https://openalex.org/W2120649968","https://openalex.org/W2127833912","https://openalex.org/W2138364630","https://openalex.org/W2146901298","https://openalex.org/W2150855258","https://openalex.org/W2152397610","https://openalex.org/W2155287847","https://openalex.org/W2167984652","https://openalex.org/W2510708214","https://openalex.org/W2554729258","https://openalex.org/W7012063851"],"related_works":["https://openalex.org/W2087539094","https://openalex.org/W2068171948","https://openalex.org/W2793397887","https://openalex.org/W2060263164","https://openalex.org/W1982905493","https://openalex.org/W2096636509","https://openalex.org/W2083210764","https://openalex.org/W2074989651","https://openalex.org/W2031730303","https://openalex.org/W1558469318"],"abstract_inverted_index":{"AIMS:":[0],"We":[1],"examined":[2],"the":[3,176,200,205,229],"efficacy,":[4],"safety":[5,85],"and":[6,26,40,63,76,91,150,156,169,244],"tolerability":[7],"of":[8,42,202,210],"canagliflozin,":[9],"a":[10,81],"sodium":[11],"glucose":[12,72],"co-transporter":[13],"2":[14,21],"inhibitor,":[15],"in":[16,68,136,140,175,199,204,248],"Japanese":[17,249],"patients":[18,98,250],"with":[19,34,235,251],"type":[20],"diabetes":[22],"(T2DM)":[23],"undergoing":[24],"diet":[25],"exercise":[27],"therapy.":[28],"METHODS:":[29],"Patients":[30],"aged":[31],"20-80":[32],"years":[33],"T2DM":[35],"diagnosed":[36],"\u22653":[37],"months":[38],"previously,":[39],"HbA1c":[41,137],"6.9-9.9%":[43],"were":[44,66,99,138,192,215],"randomized":[45,100],"to":[46,101,145],"50,":[47,153],"100,":[48,154],"200":[49,119,155],"or":[50,54,108,124,188,218,228],"300":[51,125,157],"mg":[52,110,115,120,126],"canagliflozin":[53,127,142,177,206,236],"placebo":[55,104,146],"once":[56],"daily":[57],"for":[58,152,162,237],"12":[59,238],"weeks.":[60],"The":[61,84,208],"primary":[62],"secondary":[64],"endpoints":[65],"changes":[67],"HbA1c,":[69],"fasting":[70],"plasma":[71],"(FPG),":[73],"urinary":[74,230],"glucose/creatinine":[75],"postprandial":[77,170],"glycaemic":[78,171,242],"parameters":[79,172],"following":[80],"meal":[82],"test.":[83],"assessments":[86],"included":[87],"adverse":[88],"events":[89],"(AEs)":[90],"clinical":[92],"laboratory":[93],"tests.":[94],"RESULTS:":[95],"Overall,":[96],"383":[97],"receive":[102],"either":[103],"(n":[105,111,116,121,128],"=":[106,112,117,122,129],"75),":[107],"50":[109],"82),":[113],"100":[114],"74),":[118],"77)":[123],"75).":[130],"At":[131],"week":[132],"12,":[133],"significant":[134],"reductions":[135],"observed":[139],"all":[141],"groups":[143],"relative":[144],"(-0.61,":[147],"-0.80,":[148],"-0.79":[149],"-0.88%":[151],"mg,":[158],"respectively,":[159],"versus":[160],"+0.11%":[161],"placebo;":[163],"all,":[164],"p":[165],"<":[166],"0.01).":[167],"FPG":[168],"improved":[173,241],"significantly":[174,182,240],"groups.":[178,207],"Body":[179],"weight":[180,247],"was":[181,195,212,254],"decreased":[183],"by":[184],"canagliflozin.":[185],"No":[186],"deaths":[187],"drug-related":[189],"serious":[190],"AEs":[191,203],"reported.":[193],"There":[194],"no":[196],"dose-dependent":[197],"increase":[198],"incidence":[201,209],"hypoglycaemia":[211],"low;":[213],"episodes":[214],"not":[216,223],"severe":[217],"dose":[219],"dependent.":[220],"Canagliflozin":[221,253],"did":[222],"affect":[224],"serum":[225],"creatinine":[226],"levels":[227],"albumin/creatinine":[231],"ratio.":[232],"CONCLUSIONS:":[233],"Treatment":[234],"weeks":[239],"control":[243],"reduced":[245],"body":[246],"T2DM.":[252],"well":[255],"tolerated.":[256]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1999892123","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":10},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":15},{"year":2016,"cited_by_count":21},{"year":2015,"cited_by_count":16},{"year":2014,"cited_by_count":28},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
